#151223

Anti-VEGF [VG76e]

Cat. #151223

Anti-VEGF [VG76e]

Cat. #: 151223

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Vascular Endothelial Growth Factor (VEGF)

Class: Monoclonal

Application: ELISA ; IHC ; WB

Reactivity: Human ; Mouse ; Primate

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Roy Bicknell

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-VEGF [VG76e]
  • Clone: VG76e
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 38-44 kDa
  • Reactivity: Human ; Mouse ; Primate
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Description: Monoclonal antibody with use investigating MVCD1, angiogenesis and various cancers.
  • Immunogen: Human VEGF189 expressed in E. coli.
  • Immunogen uniprot id: P15692
  • Isotype: IgG1 kappa
  • Myeloma used: P3/NS1/1-Ag4.1
  • Recommended controls: VEGF recombinant protein.

Target Details

  • Target: Vascular Endothelial Growth Factor (VEGF)
  • Molecular weight: 38-44 kDa
  • Tissue cell line specificity: VEGF recombinant protein.
  • Target background: VEGF is a 34-43 kD polypeptide growth factor, part of the PDGF family. There are 7 homo-dimeric isoforms (A-G) with VEGF 121, VEGF 165 and VEGF189 being the most extensively studied (F,D and B respectively). They are generated by alternative splicing and binding to VEGF receptors (FLT-1 and KDR) which are selectively expressed on vascular endothelial cells. VEGF elicits mitogenic effects on endothelial cells and is strongly angiogenic, with a role in cancer and metastasis. VEGF is involved in vasculogenesis and endothelial growth. VEGF expression is potentiated, and the protein is secreted by tumour cells in response to hypoxia, by activated oncogenes, growth factors, nitric oxide and a variety of cytokines. Defects in VEGFA are linked to MVCD1 (microvascular complications of diabetes type 1) and VEGF polymorphisms are associated with susceptibility to multiple cancers, e.g. glioma, HCC, ovarian, bladder, prostate, breast cancer etc. VEGF is an angiogenic growth factor and a prognostic indicator for cancer when detected in serum. This antibody binds VEGF-A.

Applications

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • Kimoto et al. 2019. Nucleic Acids Res. 47(16):8362-8374. PMID: 31392985.
  • Tan et al. 2017. Sci Rep. 7(1):3504. PMID: 28615707.
  • Leonhäuser et al. 2017. J Transl Med. 15(1):3. PMID: 28049497.
  • Butler et al. 2011. Am J Physiol Cell Physiol. 301(3):C653-66. PMID: 21653901.
  • Contributions of VEGF to age-dependent transmural gradients in contractile protein expression in ovine carotid arteries.
  • de Queiroz et al. 2010. J Vet Diagn Invest. 22(1):105-8. PMID: 20093695.
  • Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs.
  • Mariani et al. 2006. Theriogenology. 66(6-7):1715-20. PMID: 16569426.
  • Immunohistochemical localization of VEGF and its receptors in the corpus luteum of the bitch during diestrus and anestrus.
  • Brown et al. 2005. Br J Cancer. 92(9):1696-701. PMID: 15841086.
  • Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
  • Bouziotis et al. 2003. Anticancer Res. 23(3A):2167-71. PMID: 12894592.
  • Samarium-153 and technetium-99m-labeled monoclonal antibodies in angiogenesis for tumor visualization and inhibition.
  • Zhang et al. 1998. J Pathol. 185(4):402-8. PMID: 9828839.
  • Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium.
  • Epstein et al. 1975. J Am Podiatry Assoc. 65(12):1131-6. PMID: 1238455.
  • Malpractice and PSROs.